Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer : recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group
(2021) In The Lancet Oncology 22(2). p.68-80- Abstract
Patients with childhood, adolescent, and young adult cancer who will be treated with gonadotoxic therapies are at increased risk for infertility. Many patients and their families desire biological children but effective communication about treatment-related infertility risk and procedures for fertility preservation does not always happen. The PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group reviewed the literature and developed a clinical practice guideline that provides recommendations for ongoing communication methods for fertility preservation for patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger and their families.... (More)
Patients with childhood, adolescent, and young adult cancer who will be treated with gonadotoxic therapies are at increased risk for infertility. Many patients and their families desire biological children but effective communication about treatment-related infertility risk and procedures for fertility preservation does not always happen. The PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group reviewed the literature and developed a clinical practice guideline that provides recommendations for ongoing communication methods for fertility preservation for patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger and their families. Moreover, the guideline panel formulated considerations of the ethical implications that are associated with these procedures. Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the evidence and recommendations. In this clinical practice guideline, existing evidence and international expertise are combined to develop transparent recommendations that are easy to use to facilitate ongoing communication between health-care providers and patients with childhood, adolescent, and young adult cancer who might be at high risk for fertility impairment and their families.
(Less)
- author
- author collaboration
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- in
- The Lancet Oncology
- volume
- 22
- issue
- 2
- pages
- 68 - 80
- publisher
- Elsevier
- external identifiers
-
- scopus:85100094498
- pmid:33539755
- ISSN
- 1470-2045
- DOI
- 10.1016/S1470-2045(20)30595-7
- language
- English
- LU publication?
- yes
- id
- 1f4bf315-827c-46eb-ad95-55e53b07d337
- date added to LUP
- 2021-12-27 14:51:38
- date last changed
- 2024-05-18 21:48:15
@article{1f4bf315-827c-46eb-ad95-55e53b07d337,
abstract = {{<p>Patients with childhood, adolescent, and young adult cancer who will be treated with gonadotoxic therapies are at increased risk for infertility. Many patients and their families desire biological children but effective communication about treatment-related infertility risk and procedures for fertility preservation does not always happen. The PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group reviewed the literature and developed a clinical practice guideline that provides recommendations for ongoing communication methods for fertility preservation for patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger and their families. Moreover, the guideline panel formulated considerations of the ethical implications that are associated with these procedures. Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the evidence and recommendations. In this clinical practice guideline, existing evidence and international expertise are combined to develop transparent recommendations that are easy to use to facilitate ongoing communication between health-care providers and patients with childhood, adolescent, and young adult cancer who might be at high risk for fertility impairment and their families.</p>}},
author = {{Mulder, Renée L. and Font-Gonzalez, Anna and van Dulmen-den Broeder, Eline and Quinn, Gwendolyn P. and Ginsberg, Jill P. and Loeffen, Erik A.H. and Hudson, Melissa M. and Burns, Karen C. and van Santen, Hanneke M. and Berger, Claire and Diesch, Tamara and Dirksen, Uta and Giwercman, Aleksander and Gracia, Clarisa and Hunter, Sarah E. and Kelvin, Joanne F. and Klosky, James L. and Laven, Joop S.E. and Lockart, Barbara A. and Neggers, Sebastian J.C.M.M. and Peate, Michelle and Phillips, Bob and Reed, Damon R. and Tinner, Eva Maria E. and Byrne, Julianne and Veening, Margreet and van de Berg, Marleen and Verhaak, Chris M. and Anazodo, Antoinette and Rodriguez-Wallberg, Kenny and van den Heuvel-Eibrink, Marry M. and Asogwa, Ogechukwu A. and Brownsdon, Alexandra and Wallace, W. Hamish and Green, Daniel M. and Skinner, Roderick and Haupt, Riccardo and Kenney, Lisa B. and Levine, Jennifer and van de Wetering, Marianne D. and Tissing, Wim J.E. and Paul, Norbert W. and Kremer, Leontien C.M. and Inthorn, Julia}},
issn = {{1470-2045}},
language = {{eng}},
number = {{2}},
pages = {{68--80}},
publisher = {{Elsevier}},
series = {{The Lancet Oncology}},
title = {{Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer : recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group}},
url = {{http://dx.doi.org/10.1016/S1470-2045(20)30595-7}},
doi = {{10.1016/S1470-2045(20)30595-7}},
volume = {{22}},
year = {{2021}},
}